EMAIL THIS PAGE TO A FRIEND

Journal of hematology & oncology

Insulin like growth factor binding protein 7 (IGFBP7) expression is linked to poor prognosis but may protect from bone disease in multiple myeloma.


PMID 25887188

Abstract

Insulin like growth factor binding protein 7 (IGFBP7) is a secreted protein binding insulin like growth factor 1 (IGF-1), insulin, vascular endothelial growth factor A (VEGFA), and activin A. It antagonizes bone morphogenetic proteins and is involved in the tumour propagation of solid as well as haematological malignancies. Its role in multiple myeloma (MM) is not defined so far. We therefore aim here to investigate its prognostic and pathophysiological role in MM. The clinical significance of IGFBP7 gene expression was investigated by gene expression profiling in two independent cohorts (n = 948) of newly-diagnosed MM patients. Methylation of the IGFBP7 promoter was analysed by pyrosequencing and treatment of MM cell lines with 5-aza-2-deoxycytidine. The impact of IGFBP7 on MM cells was studied by CCK-8 assay, BrdU assay and flow cytometry, respectively. IGFBP7 expression in bone marrow stromal cells (BMSCs) was studied by quantitative RT-PCR. For osteoblast development, immortalized and primary human BMSCs were cultured in osteogenic differentiation medium for 7-14 days in the presence of recombinant human IGFBP7 and/or activin A. Median IGFBP7 expression is significantly lower in CD138-purified plasma cells from individuals with MGUS and MM, compared to normal bone marrow plasma cells. IGFBP7 gene expression in MM cells is regulated by methylation, shown by pyrosequencing and exposure to demethylating agents (5-aza-2-deoxycytidine). High expression of IGFBP7 in MM cells is associated with adverse survival in two independent cohorts of 247 and 701 newly-diagnosed MM patients treated with high-dose therapy and autologous stem cell transplantation. IGFBP7 is associated with prognostically adverse chromosomal aberrations (t(4;14) and gain of 1q21), MMSET expression, and higher myeloma cell proliferation. In vitro, IGFBP7 overcomes activin A induced osteoblast suppression and promotes osteogenesis. MM cells downregulate IGFBP7 in stromal cells, possibly contributing to the osteoblast suppression found in MM. Conversely, higher IGFBP7 expression is associated with a lower probability of myeloma bone disease. Our data indicate that IGFBP7 expression is a marker for a specific methylation pattern in myeloma, linked to translocation t(4;14) associated MMSET expression, showing clinical features of adverse prognosis with absence of myeloma bone disease.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

1043003
Ascorbic acid, United States Pharmacopeia (USP) Reference Standard
C6H8O6
A1300000
Ascorbic acid, European Pharmacopoeia (EP) Reference Standard
C6H8O6
PHR1008
Ascorbic Acid, Pharmaceutical Secondary Standard; Certified Reference Material
C6H8O6
C106
CGS-12066 maleate salt, solid
C17H17F3N4 · C4H4O4
PHR1526
Dexamethasone, Pharmaceutical Secondary Standard; Certified Reference Material
C22H29FO5
1176007
Dexamethasone, United States Pharmacopeia (USP) Reference Standard
C22H29FO5
D0700000
Dexamethasone, European Pharmacopoeia (EP) Reference Standard
C22H29FO5
46165
Dexamethasone, VETRANAL®, analytical standard
C22H29FO5
31375
Dexamethasone, tested according to Ph Eur
C22H29FO5
BP578
Dexamethasone, British Pharmacopoeia (BP) Assay Standard
C22H29FO5
Y0001593
Dexamethasone for peak identification, European Pharmacopoeia (EP) Reference Standard
C22H29FO5
Y0001177
Dexamethasone for system suitability, European Pharmacopoeia (EP) Reference Standard
C22H29FO5
01934
Dimethyl sulfoxide, for inorganic trace analysis, ≥99.99995% (metals basis)
C2H6OS
94563
Dimethyl sulfoxide, analytical standard
C2H6OS
1211006
Dimethyl sulfoxide, United States Pharmacopeia (USP) Reference Standard
C2H6OS
D2050000
Dimethyl sulfoxide, European Pharmacopoeia (EP) Reference Standard
C2H6OS
PHR1014
Hydrocortisone, Pharmaceutical Secondary Standard; Certified Reference Material
C21H30O5
1316004
Hydrocortisone, United States Pharmacopeia (USP) Reference Standard
C21H30O5
H1300000
Hydrocortisone, European Pharmacopoeia (EP) Reference Standard
C21H30O5
31719
Hydrocortisone, VETRANAL®, analytical standard
C21H30O5
BP576
Hydrocortisone, British Pharmacopoeia (BP) Assay Standard
C21H30O5
Y0001092
Hydrocortisone for peak identification, European Pharmacopoeia (EP) Reference Standard
C21H30O5
95212
L-Ascorbic acid, tested according to Ph Eur
C6H8O6
57803
L-Ascorbic acid, certified reference material, TraceCERT®
C6H8O6
76523
L-Glutamine, certified reference material, TraceCERT®
C5H10N2O3
PHR1125
L-Glutamine, Pharmaceutical Secondary Standard; Certified Reference Material
C5H10N2O3